Perfil
David Green worked as an Executive Director of Clinical Operations at Amgen, Inc. from 1997 to 2008.
He also worked as an Executive Director at United Therapeutics Corp., a Clinical Program Manager at Abbott Laboratories, and a Vice President of Global Clinical Operations at both Aquinox Pharmaceuticals, Inc. and ReSearch Pharmaceutical Services, Inc.
Antiguos cargos conocidos de David Green.
| Empresas | Cargo | Fin |
|---|---|---|
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/02/2008 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| UNITED THERAPEUTICS CORPORATION | Director/Board Member | - |
| ReSearch Pharmaceutical Services, Inc. | Chief Tech/Sci/R&D Officer | - |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| AMGEN INC. | Health Technology |
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| Empresas privadas | 2 |
|---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| ReSearch Pharmaceutical Services, Inc. |
- Bolsa de valores
- Insiders
- David Green
